Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-02

Clinical Trial Update: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Grazoprevir with Uprifosbuvir with Elbasvir or Ruzasvir for chronic Hepatitis C across genotypes 3-6; study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Elbasvir (elbasvir)
  • Grazoprevir (grazoprevir)
  • Ruzasvir (ruzasvir)
  • Uprifosbuvir (uprifosbuvir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2018-07-02